HC Wainwright Issues Positive Forecast for NKTR Earnings

Nektar Therapeutics (NASDAQ:NKTR) – Analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for shares of Nektar Therapeutics in a report issued on Thursday, March 13th. HC Wainwright analyst A. He now expects that the biopharmaceutical company will post earnings of ($0.15) per share for the quarter, up from their prior forecast of ($0.17). HC Wainwright has a “Buy” rating and a $6.50 price objective on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Nektar Therapeutics’ Q2 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.68) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at ($0.79) EPS, FY2028 earnings at ($0.87) EPS and FY2029 earnings at ($0.52) EPS.

A number of other equities analysts have also recently issued reports on the company. Oppenheimer upgraded Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 price objective for the company in a report on Friday, March 14th. B. Riley began coverage on Nektar Therapeutics in a report on Wednesday, January 8th. They issued a “buy” rating and a $4.00 target price for the company. Finally, William Blair reiterated a “market perform” rating on shares of Nektar Therapeutics in a report on Thursday, March 13th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Nektar Therapeutics has a consensus rating of “Buy” and an average price target of $4.92.

Nektar Therapeutics Stock Down 3.2 %

NKTR opened at $0.88 on Monday. The business has a fifty day moving average of $0.87 and a 200 day moving average of $1.07. Nektar Therapeutics has a 52-week low of $0.65 and a 52-week high of $1.93. The stock has a market cap of $162.36 million, a P/E ratio of -1.05 and a beta of 0.65.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Wednesday, March 12th. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.33. The firm had revenue of $29.18 million for the quarter, compared to the consensus estimate of $36.65 million. Nektar Therapeutics had a negative return on equity of 173.28% and a negative net margin of 180.70%.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Two Sigma Securities LLC boosted its stake in shares of Nektar Therapeutics by 56.3% in the fourth quarter. Two Sigma Securities LLC now owns 27,654 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 9,958 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Nektar Therapeutics by 6.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 192,978 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 10,941 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Nektar Therapeutics by 12.2% in the fourth quarter. SG Americas Securities LLC now owns 107,318 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 11,681 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Nektar Therapeutics by 0.9% in the fourth quarter. Northern Trust Corp now owns 1,414,984 shares of the biopharmaceutical company’s stock worth $1,316,000 after buying an additional 12,826 shares during the last quarter. Finally, Moloney Securities Asset Management LLC boosted its stake in shares of Nektar Therapeutics by 42.4% in the fourth quarter. Moloney Securities Asset Management LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 14,895 shares during the last quarter. 75.88% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Nektar Therapeutics

In related news, insider Mark Andrew Wilson sold 33,402 shares of the company’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $0.90, for a total transaction of $30,061.80. Following the transaction, the insider now directly owns 351,892 shares of the company’s stock, valued at $316,702.80. This represents a 8.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Jonathan Zalevsky sold 51,115 shares of the company’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $0.94, for a total value of $48,048.10. Following the transaction, the insider now directly owns 326,904 shares in the company, valued at $307,289.76. This represents a 13.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 118,591 shares of company stock valued at $112,525 in the last ninety days. Corporate insiders own 3.71% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.